The limit of a two-state measure
In the pancreatic cancer work, Quine ranked thousands of compounds by their potential to move tumor cells between classical and basal states. In assays with the Broad Institute, some highly ranked compounds produced the intended shift. The team narrowed candidates over one weekend. The laboratory result shows that this rapid ranking worked under the tested cell conditions.[1]
The more revealing result was that the reverse transition was weaker and some compounds moved cells toward a third state. A score built around two endpoints could make that third state look like incidental variation. Yet the identity of the resulting cell state determines which biological question a compound has answered. For me, the decisive evaluation detail is how those states were defined, alongside how many candidates reached the top of the list.[1]
The experiment after speed
Microsoft describes Quine as research technology and says it is not intended for clinical use. Changing a cell state in a laboratory assay does not measure a patient’s treatment outcome. At this stage, the work offers a way to reduce the number of compounds that require testing and raises a new question about the unexpected third state. The latter depends on carrying experimental data that challenge the initial picture back into the research loop.[1]
The third-state shift may arise from a different effect of a compound; properties of the particular cell models are another plausible explanation. Testing the same compounds in new samples with state definitions set beforehand would help separate those possibilities. A consistent direction across samples would strengthen Quine as a research tool. If the direction changes, the weekend saved in candidate selection remains real, while the biological meaning of the selected target needs another look.[1]